⌘K
Loading ticker…
As of 2026-08-24, Roivant Sciences Ltd. Common Shares (ROIV) has a 3-month relative strength percentile of 82 and a leadership percentile of 96 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 72. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 3.5%, relative volume 0.89×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ROIV is in a stage 2 uptrend, week 11. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 5.1% / 30.6%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
ROIV is held by 27 ETFs as of May 2026. Top owner: VHT at 0.18% weight, $34M notional. Top 3 carry $66M.
Held by 58 ETFs · $1.4B across latest filings · largest weight 4.65% (PTH).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VHTVanguard Health Care ETF | 0.18% | $34M | +0.02 pp |
| IVOO | 0.39% | $22M | +0.02 pp |
| QQQJ | 1.00% | $11M | — |
| VONVVanguard Russell 1000 Value ETF | 0.04% | $8M | — |
| IVOG | 0.43% | $8M | +0.02 pp |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.30% |
| $5M |
| −0.21 pp |
| IVOV | 0.34% | $5M | +0.02 pp |
| ESML | 0.15% | $4M | +0.01 pp |
| ESGV | 0.02% | $3M | — |
| AVUSAvantis U.S. Equity ETF | 0.02% | $2M | — |
Showing 10 of 27 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ROIV Jan avg: -3.34% median: -3.14% win: 25% σ: 6.47% n: 4 2022-04-12 → 2026-07-31 | ROIV Feb avg: 10.56% median: 5.93% win: 50% σ: 17.57% n: 4 2022-04-12 → 2026-07-31 | ROIV Mar avg: -6.74% median: -6.96% win: 0% σ: 1.99% n: 4 2022-04-12 → 2026-07-31 | ROIV Apr avg: 5.57% median: 3.42% win: 80% σ: 10.46% n: 5 2022-04-12 → 2026-07-31 | ROIV May avg: 4.28% median: 5.12% win: 60% σ: 10.51% n: 5 2022-04-12 → 2026-07-31 | ROIV Jun avg: 5.03% median: 2.55% win: 80% σ: 9.96% n: 5 2022-04-12 → 2026-07-31 | ROIV Jul avg: 3.18% median: 0.80% win: 60% σ: 9.15% n: 5 2022-04-12 → 2026-07-31 | ROIV Aug avg: 0.94% median: 0.80% win: 50% σ: 10.11% n: 4 2022-04-12 → 2026-07-31 (current) | ROIV Sep avg: 3.15% median: -2.35% win: 50% σ: 16.37% n: 4 2022-04-12 → 2026-07-31 | ROIV Oct avg: 16.45% median: 16.10% win: 75% σ: 37.34% n: 4 2022-04-12 → 2026-07-31 | ROIV Nov avg: 7.27% median: 7.16% win: 100% σ: 3.56% n: 4 2022-04-12 → 2026-07-31 | ROIV Dec avg: 15.97% median: 10.87% win: 75% σ: 24.21% n: 4 2022-04-12 → 2026-07-31 |